|
市場調查報告書
進軍肥胖治療藥物市場的藥劑為何
Will Anyone Crack theObesity Drug Market?
|
進軍肥胖治療藥物市場的藥劑為何 是由出版商Espicom Business Intelligence在2011年02月所出版的。
這份英文市場調查報告書包含Pages: 102 價格從美金2615起跳。
世界衛生組織表示，全球成人中每3人中有1人，且未滿5歲孩童中2,000萬人體重過重，10％成年人有肥胖問題。2010年12月，FDA雖希望正面放寬Orexigen之Naltrexone緩釋及bupropion SR組合藥物之Contrave，結果終究無法給予Contrave許可，並進一步要求更多的臨床實驗。若此藥物被許可，作為此10年間針對肥胖藥理之治療藥物，治療肥胖的選項一定早已倍增。目前歐美被許可的肥胖治療藥物只有Roche之Xenical，GlaxoSmithKline也只會讓OTC版的Alli上市。
本報告為，綜合分析肥胖治療藥物之開發趨勢，並匯整目前市場趨勢及未來展望、開發階段別產品概要等，以下列摘要形式闡述。
序
實施概要
市場分析
- 目前市場
- 未來市場
- 研究開發
- 背景資訊
- 何謂肥胖
- 肥胖的原因
- 肥胖的健康風險
- 控制能量平衡
- 達成減重
- 為何必須要有新的治療方式
- 肥胖之盛行率
產品分析
- 已確定的產品
- 近來撤回之產品
- 已經註冊之產品
- 第3相
- 第2相
- Betahistine
- Pramlintde+metreleptin
- SLx-4090
- Tesofensine
- TM30339
- Velneperit
- Zonisamide+bupropion
- 第1／2相
- BMS-830216
- obinepitide
- 作用機轉
- 現況
- 概念驗證／臨床實驗數據
- 開發風險
- 企業之專業度
- 市場競合
調查方式
Abstract
Summary
Following the FDA' s decision on Orexigen' s Contrave, the question is: Will a
successful obesity drug market ever develop?
SUse this report to:
- Understand the state of play with Orexigen' s Contrave
- Review the prevalence and impact of obesity
- Evaluate the therapeutic approaches being undertaken
- Critically assess and compare the approach and potential of products in
clinical research with our unique product scoring
SCategory
Pharmaceuticals, Healthcare, Company, Market,
SMETA Description
Around one in three of the global adult population and more than 20 million
children under five are overweight according to the World Health Organization.
Around 10% of adults are obese. In the US, an estimated 44.2% of males and
48.3% of females have a body mass index (BMI) of 30 or more and are classified
as obese.
SOrexigen' s Contrave: possibly a new chapter - but when?
In December 2010, the FDA' s Endocrinologic and Metabolic Drugs Advisory
Committee voted positively in favour of Orexigen' s naltrexone
sustained-release (SR) and bupropion SR combination, Contrave. The market was
then surprised when the FDA did not approve the drug, asking instead for
further clinical trials. If Contrave had been approved, it would have been the
first new pharmacological treatment for obesity for more than a decade and
would have immediately doubled the choice of available therapies; currently
the only prescription drug that remains approved for obesity in the US and EU
is Roche' s Xenical (orlistat), a low-dose OTC version of which is marketed by
GlaxoSmithKline as alli.
- Report contents summary
- Executive summary
- Current market
- Future market
- Background information
- Product analysis by phase of development
This new report Will Anyone Crack the Obesity Drug Market, (published February
2011) provides a complete review of this difficult to develop area. Please
note that web access is included at no additional cost.
Table of Contents
FOREWORD
EXECUTIVE SUMMARY
MARKET ANALYSIS
- CURRENT MARKET
- Sibutramine
- Rimonabant
- Orlistat
- FUTURE MARKET
- Research and Development
- Endogenous Hormones
- Monoamine Neurotransmission Modulation
- Neuropeptide Signalling Modulators
- Peripheral Modulators of Metabolism
- Regulation of Fat Metabolism and Food Intake: a Novel Approach?
- BACKGROUND INFORMATION
- What is Obesity?
- What Causes Obesity
- Obesity Health Risks
- Controlling Energy Balance
- Achieving Weight Loss
- Lifestyle Modifications
- Behaviour Therapy
- Pharmacotherapy
- Surgery
- Why are New Treatments Needed?
- The Prevalence of Obesity
- Childhood Obesity
PRODUCT ANALYSIS
- ESTABLISHED PRODUCT
- Orlistat
- Mode of Action
- Current Status
- Approvals/Filings
- Development
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Low-dose Orlistat.
- Xenical in Adolescents
- Diabetes Prevention in Obese Subjects
- RECENTLY WITHDRAWN PRODUCT
- Sibutramine
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Clinical Trial Results
- FILED PRODUCTS
- Bupropion+naltrexone
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Contrave Obesity Research (COR)
- Lorcaserin
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- BLOSSOM
- BLOOM
- BLOOM-DM
- Abuse Potential
- Phentermine+topiramate
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Long-Term Date Show Significant and Sustained Weight Loss Over Two
Years
- EQUIP (OB-302) and CONQUER (OB-303) Obesity Studies
- EQUATE Obesity Study
- Sleep Apnoea Phase II Study
- PHASE III
- Cetilistat
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Liraglutide
- Mode of Action
- Current Status
- Approvals/Filings
- Development
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Data Exclusivity
- Patent Expiry
- Competitor Ratio Analysis
- Clinical Trial Results
- PHASE II
- Betahistine
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Pramlintide+metreleptin
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- SLx-4090
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Phase II - Dyslipidaemia
- Phase I - Dyslipidaemia
- Phase I - Safety and Tolerability
- Tesofensine
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- TIPO-5
- TIPO-4
- TIPO-2
- TIPO-1
- Cardiovascular Safety Study
- TM30339
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Clinical Trial Results
- Velneperit
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Zonisamide+bupropion
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Phase IIb
- Post hoc analyses.
- Phase IIb results at 48 weeks
- Phase IIb results at 24 weeks
- PHASE I/II
- BMS-830216
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Obinepitide
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Clinical Trial Results
METHODOLOGY
- Competitor Ratio Analysis Criteria
List of Tables
- Competitor Ratio Analysis Summary
- Drugs in Clinical Development for Obesity
- Relative Risks of Health Problems Associated with Obesity
- The Benefits of 10kg Weight Loss
List of Figures
- Global Prevalence of Obesity, 2010
- Adult Male BMI kg/m2 in Selected Countries, 2010 (%)
- Adult Female BMI kg/m2 in Selected Countries, 2010 (%)
- Weight Loss Achieved With Orlistat
|
